| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8239920 | International Journal of Radiation Oncology*Biology*Physics | 2008 | 8 Pages |
Abstract
SRT is well tolerated in patients with extensive comorbidity with high local control rates and minimal toxicity. Early outcomes are not inferior to those reported for conventional radiotherapy. In view of patient convenience, such risk-adapted SRT schedules should be considered treatment of choice in patients presenting with medically inoperable Stage I NSCLC.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Frank J. M.D., Ph.D., Cornelis J.A. M.D., Egbert F. M.D., Ph.D., Ben J. M.D., Ph.D., S. M.R.C.P., F.R.C.R., Ph.D.,